EGFR and lung carcinoma: Quinazoline derivatives were found to exhibit good inhibitory activities against the epidermal growth factor receptor (EGFR) by X. Wu, J. Zhang, et al. [9] Notably, certain lung cancer cells tend to evolve with EGFR mutations, which cause their abnormal proliferation and thus accelerate cancer progression.